Skip to main content

Table 3 Progression of CAC volume and score between the ICI and the non-ICI group at 12 months after PSM

From: Immune checkpoint inhibitors in cancer: the increased risk of atherosclerotic cardiovascular disease events and progression of coronary artery calcium

 

ICI group (IQR)

Non-ICI group (IQR)

p-values*

Absolute volume progression (mm3)

22.1 (6.2, 52.1)

8.3 (2.8, 30.2)

0.013

Absolute score progression

26.6 (6.6, 69.9)

12.4 (1.6, 24.2)

0.002

Relative volume progression (%)

30.4 (13.5, 50.3)

19.7 (5.6, 31.0)

0.004

Relative score progression (%)

30.6 (18.7, 48.6)

19.4 (5.3, 34.3)

0.003

  1. Abbreviations: CAC coronary artery calcium, ICI immune checkpoint inhibitor, IQR interquartile range, PSM propensity score matching
  2. *Wilcoxon rank-sum test comparing progression of CAC volume and score between the ICI group with the non-ICI group
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us